Ad hoc vs. Non-ad hoc Percutaneous Coronary Intervention Strategies in Patients With Stable Coronary Artery Disease

1. Guidelines for percutaneous transluminal coronary angioplasty. A report of the American College of Cardiology/American Heart Association Task Force on Assessment of Diagnostic and Therapeutic Cardiovascular Procedures (Subcommittee on Percutaneous Transluminal Coronary Angioplasty). <i>J Am Coll Cardiol</i> 1988; 12: 529–545.

2. Smith SC Jr, Dove JT, Jacobs AK, Kennedy JW, Kereiakes D, Kern MJ, et al. ACC/AHA guidelines of percutaneous coronary interventions (revision of the 1993 PTCA guidelines) – executive summary: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (committee to revise the 1993 guidelines for percutaneous transluminal coronary angioplasty). <i>J Am Coll Cardiol</i> 2001; 37: 2215–2239.

3. Levine GN, Bates ER, Blankenship JC, Bailey SR, Bittl JA, Cercek B, et al. 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. <i>J Am Coll Cardiol</i> 2011; 58: e44–e122.

4. Levine GN, O’Gara PT, Bates ER, Blankenship JC, Kushner FG, Bailey SR, et al. 2015 ACC/AHA/SCAI Focused Update on Primary Percutaneous Coronary Intervention for Patients With ST-Elevation Myocardial Infarction: An Update of the 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention and the 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction. A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. <i>J Am Coll Cardiol</i> 2016; 67: 1235–1250.

5. Blankenship JC, Gigliotti OS, Feldman DN, Mixon TA, Patel RA, Sorajja P, et al. Ad hoc percutaneous coronary intervention: A consensus statement from the Society for Cardiovascular Angiography and Interventions. <i>Catheter Cardiovasc Interv</i> 2013; 81: 748–758.

6. Authors/Task Force members, Windecker S, Kolh P, Alfonso F, Collet JP, Cremer J, et al. 2014 ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). <i>Eur Heart J</i> 2014; 35: 2541–2619.

7. Kimmel SE, Berlin JA, Hennessy S, Strom BL, Krone RJ, Laskey WK. Risk of major complications from coronary angioplasty performed immediately after diagnostic coronary angiography: Results from the Registry of the Society for Cardiac Angiography and Interventions. <i>J Am Coll Cardiol</i> 1997; 30: 193–200.

8. Goldstein CL, Racz M, Hannan EL. Impact of cardiac catheterization-percutaneous coronary intervention timing on inhospital mortality. <i>Am Heart J</i> 2002; 144: 561–567.

9. Krone RJ, Shaw RE, Klein LW, Blankenship JC, Weintraub WS, American College of Cardiology-National Cardiovascular Data Registry. Ad hoc percutaneous coronary interventions in patients with stable coronary artery disease: A study of prevalence, safety, and variation in use from the American College of Cardiology National Cardiovascular Data Registry (ACC-NCDR). <i>Catheter Cardiovasc Interv</i> 2006; 68: 696–703.

10. Kim YH, Park DW, Ahn JM, Park GM, Cho YR, Lee JY, et al. Impact of ad hoc percutaneous coronary intervention with drug-eluting stents in angina patients. <i>EuroIntervention</i> 2013; 9: 110–117.

11. Hannan EL, Samadashvili Z, Walford G, Holmes DR, Jacobs A, Sharma S, et al. Predictors and outcomes of ad hoc versus non-ad hoc percutaneous coronary interventions. <i>JACC Cardiovasc Interv</i> 2009; 2: 350–356.

12. Kimura T, Morimoto T, Furukawa Y, Nakagawa Y, Kadota K, Iwabuchi M, et al. Long-term safety and efficacy of sirolimus-eluting stents versus bare-metal stents in real world clinical practice in Japan. <i>Cardiovasc Interv Ther</i> 2011; 26: 234–245.

13. Toyota T, Shiomi H, Taniguchi T, Morimoto T, Furukawa Y, Nakagawa Y, et al. Culprit vessel-only versus staged multivessel percutaneous coronary intervention strategies in patients with multivessel coronary artery disease undergoing primary percutaneous coronary intervention for ST-segment elevation myocardial infarction. <i>Circ J</i> 2016; 80: 371–378.

14. Serruys PW, Ong AT, van Herwerden LA, Sousa JE, Jatene A, Bonnier JJ, et al. Five-year outcomes after coronary stenting versus bypass surgery for the treatment of multivessel disease: The final analysis of the Arterial Revascularization Therapies Study (ARTS) randomized trial. <i>J Am Coll Cardiol</i> 2005; 46: 575–581.

15. The GUSTO investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. <i>N Engl J Med</i> 1993; 329: 673–682.

16. Abe M, Morimoto T, Akao M, Furukawa Y, Nakagawa Y, Shizuta S, et al. Relation of contrast-induced nephropathy to long-term mortality after percutaneous coronary intervention. <i>Am J Cardiol</i> 2014; 114: 362–368.

17. Spargias K, Alexopoulos E, Kyrzopoulos S, Iokovis P, Greenwood DC, Manginas A, et al. Ascorbic acid prevents contrast-mediated nephropathy in patients with renal dysfunction undergoing coronary angiography or intervention. <i>Circulation</i> 2004; 110: 2837–2842.

18. Puymirat E, Taldir G, Aissaoui N, Lemesle G, Lorgis L, Cuisset T, et al. Use of invasive strategy in non-ST-segment elevation myocardial infarction is a major determinant of improved long-term survival: FAST-MI (French Registry of Acute Coronary Syndrome). <i>JACC Cardiovasc Interv</i> 2012; 5: 893–902.

19. Katritsis DG, Siontis GC, Kastrati A, van’t Hof AW, Neumann FJ, Siontis KC, et al. Optimal timing of coronary angiography and potential intervention in non-ST-elevation acute coronary syndromes. <i>Eur Heart J</i> 2011; 32: 32–40.

20. Azzalini L, Spagnoli V, Ly HQ. Contrast-induced nephropathy: From pathophysiology to preventive strategies. <i>Can J Cardiol</i> 2016; 32: 247–255.

21. McCullough PA. Contrast-induced acute kidney injury. <i>J Am Coll Cardiol</i> 2008; 51: 1419–1428.

22. Dudek D, Dziewierz A, Widimsky P, Bolognese L, Goldstein P, Hamm C, et al. Impact of prasugrel pretreatment and timing of coronary artery bypass grafting on clinical outcomes of patients with non-ST-segment elevation myocardial infarction: From the A Comparison of Prasugrel at PCI or Time of Diagnosis of Non-ST-Elevation Myocardial Infarction (ACCOAST) study. <i>Am Heart J</i> 2015; 170: 1025–1032.e1022.

23. Adele C, Vaitkus PT, Wells SK, Zehnacker JB. Cost advantages of an ad hoc angioplasty strategy. <i>J Am Coll Cardiol</i> 1998; 31: 321–325.

24. Bradley SM, Maynard C, Bryson CL. Appropriateness of percutaneous coronary interventions in Washington State. <i>Circ Cardiovasc Qual Outcomes</i> 2012; 5: 445–453.

25. De Bruyne B, Pijls NH, Kalesan B, Barbato E, Tonino PA, Piroth Z, et al. Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease. <i>N Engl J Med</i> 2012; 367: 991–1001.

26. Pijls NH, van Schaardenburgh P, Manoharan G, Boersma E, Bech JW, van’t Veer M, et al. Percutaneous coronary intervention of functionally nonsignificant stenosis: 5-year follow-up of the DEFER Study. <i>J Am Coll Cardiol</i> 2007; 49: 2105–2111.

27. Tazaki J, Shiomi H, Morimoto T, Imai M, Yamaji K, Sakata R, et al. Three-year outcome after percutaneous coronary intervention and coronary artery bypass grafting in patients with triple-vessel coronary artery disease: Observations from the CREDO-Kyoto PCI/CABG registry cohort-2. <i>EuroIntervention</i> 2013; 9: 437–445.

28. Mohr FW, Morice MC, Kappetein AP, Feldman TE, Stahle E, Colombo A, et al. Coronary artery bypass graft surgery versus percutaneous coronary intervention in patients with three-vessel disease and left main coronary disease: 5-year follow-up of the randomised, clinical SYNTAX trial. <i>Lancet</i> 2013; 381: 629–638.

29. Rumberger JA. Noninvasive coronary angiography using computed tomography: Ready to kick it up another notch? <i>Circulation</i> 2002; 106: 2036–2038.

30. Norgaard BL, Leipsic J, Gaur S, Seneviratne S, Ko BS, Ito H, et al. Diagnostic performance of noninvasive fractional flow reserve derived from coronary computed tomography angiography in suspected coronary artery disease: The NXT trial (Analysis of Coronary Blood Flow Using CT Angiography: Next Steps). <i>J Am Coll Cardiol</i> 2014; 63: 1145–1155.

31. Neglia D, Rovai D, Caselli C, Pietila M, Teresinska A, Aguade-Bruix S, et al. Detection of significant coronary artery disease by noninvasive anatomical and functional imaging. <i>Circ Cardiovasc Imaging</i> 2015; 8: e002179.